REDUCE IT Analysis Shows Benefits of Icosapent Ethyl in US Cohort
(WorldNews Health)

A U.S. cohort of the REDUCE IT trial found that icosapent ethyl had `particularly robust risk reductions across a variety of composite and individual endpoints, including all-cause mortality.` The analysis published Nov. 11 in Circulation and will be presented during AHA 2019 in Philadelphia, PA. Deepak L. Bhatt, MD, MPH, FACC, et al., looked at a prespecified group of patients from the REDUCE IT...